Patents by Inventor Andrew Bogdan

Andrew Bogdan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted Pyrrolidines and Methods of Use
    Publication number: 20190315687
    Abstract: The invention discloses compounds of Formula (I) wherein R1, R2, R2A, R3, R3A, R4, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: June 14, 2019
    Publication date: October 17, 2019
    Inventors: Robert J. Altenbach, Andrew Bogdan, Nicolas Desroy, Gregory A. Gfesser, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Marc J. Scanio, Xenia B. Searle, Xueqing Wang, Ming C. Yeung, Gang Zhao
  • Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
    Patent number: 10428017
    Abstract: The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: October 1, 2019
    Assignees: AbbVie S.á.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Andrew Bogdan, Nicolas Desroy, Gregory A. Gfesser, Stephen N. Greszler, Philip R. Kym, Bo Liu, Karine Fabienne Malagu, Nuria Merayo Merayo, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung, Gang Zhao
  • Substituted pyrrolidines and methods of use
    Patent number: 10399940
    Abstract: The invention discloses compounds of Formula (I) wherein R1, R2, R2A, R3, R3A, R4, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: September 3, 2019
    Assignees: AbbVie S.á.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Andrew Bogdan, Nicolas Desroy, Gregory A. Gfesser, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Marc J. Scanio, Xenia Searle, Xueqing Wang, Ming C. Yeung, Gang Zhao
  • Substituted Tricyclics and Method of Use
    Publication number: 20190135827
    Abstract: The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Application
    Filed: January 8, 2019
    Publication date: May 9, 2019
    Inventors: Robert J. Altenbach, Andrew Bogdan, Marlon D. Cowart, William Rameshchandra Krishna Esmieu, Gregory A. Gfesser, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Karine Fabienne Malagu, Sachin V. Patel, Marc J. Scanio, Xenia B. Searle, Eric Voight, Xueqing Wang, Ming C. Yeung
  • Substituted Chromanes and Method of Use
    Publication number: 20190127356
    Abstract: The invention provides for compounds of formula (I) wherein R1, X, Y, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, m, and R? have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Application
    Filed: December 19, 2018
    Publication date: May 2, 2019
    Inventors: Robert J. Altenbach, Andrew Bogdan, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Xenia B. Searle, Eric Voight, Xueqing Wang, Ming C. Yeung
  • Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
    Publication number: 20190077784
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: September 12, 2018
    Publication date: March 14, 2019
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • Heteroaryl Substituted Pyridines and Methods of Use
    Publication number: 20190055229
    Abstract: The invention discloses compounds of Formula I, wherein X1, X2, R1, and R2 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: October 19, 2018
    Publication date: February 21, 2019
    Inventors: Robert J. Altenbach, Andrew Bogdan, Ghjuvanni Petru Diunisu Coti, Marlon D. Cowart, Stephen N. Greszler, Hans Kelgtermans, Philip R. Kym, Steven Emiel Van der Plas, Xueqing Wang
  • BROMODOMAIN INHIBITORS
    Publication number: 20190008866
    Abstract: The present invention provides for compounds of formula (I) wherein Y1, Y2, R1, R2, R3, A1, A2, A3, and A4, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Application
    Filed: August 30, 2018
    Publication date: January 10, 2019
    Inventors: Andrew Bogdan, Warren M. Kati, Keith F. McDaniel, Chang H. Park, George S. Sheppard, Le Wang
  • Heteroaryl substituted pyridines and methods of use
    Patent number: 10138227
    Abstract: The invention discloses compounds of Formula I, wherein X1, X2, R1, and R2 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: November 27, 2018
    Assignees: AbbVie S.á.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Andrew Bogdan, Ghjuvanni Petru Diunisu Coti, Marlon D. Cowart, Stephen N Greszler, Hans Kelgtermans, Philip R Kym, Steven Emiel Van der Plas, Xueqing Wang
  • 6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE
    Publication number: 20180334435
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Application
    Filed: April 13, 2018
    Publication date: November 22, 2018
    Inventors: Andrew Bogdan, Marlon D. Cowart, David A. DeGoey, Tammie K. Jinkerson, John R. Koenig, Michael E. Kort, Bo Liu, Mark A. Matulenko, Derek W. Nelson, Meena V. Patel, Hillary Peltier, Marc J. Scanio, Brian D. Wakefield
  • Modulators of cystic fibrosis transmembrane conductance regulator protein
    Patent number: 10118916
    Abstract: The present invention provides for compounds of formula (I) wherein R1, m, Z, G1, R2, and R3 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: November 6, 2018
    Assignees: AbbVie S.á.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Andrew Bogdan, Vincent Chan, Timothy A. Grieme, John R. Koenig, Philip R. Kym, Bo Liu, Karine Fabienne Malagu, Sachin V. Patel, Marc Scanio, Xenia B. Searle, Shashank Shekhar, Xueqing Wang, Ming C. Yeung
  • TETRACYCLIC BROMODOMAIN INHIBITORS
    Publication number: 20180298003
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, Y3, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Application
    Filed: June 26, 2018
    Publication date: October 18, 2018
    Inventors: Steven D. Fidanze, Dachun Liu, Robert A. Mantei, Keith F. McDaniel, John Pratt, George S. Sheppard, Le Wang, Andrew Bogdan, James H. Holms, Justin D. Dietrich, Jasmina Marjanovic, Lisa A. Hasvold, Yujia Dai
  • Bromodomain inhibitors
    Patent number: 10085985
    Abstract: The present invention provides for compounds of formula (I) wherein Y1, Y2, R1, R2, R3, A1, A2, A3, and A4, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: October 2, 2018
    Assignee: AbbVie Inc.
    Inventors: Andrew Bogdan, Warren M. Kati, Keith F. McDaniel, Chang H. Park, George S. Sheppard, Le Wang
  • Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
    Publication number: 20180244640
    Abstract: The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: February 22, 2018
    Publication date: August 30, 2018
    Inventors: Robert J. Altenbach, Andrew Bogdan, Nicolas Desroy, Gregory A. Gfesser, Stephen N. Greszler, Philip R. Kym, Bo Liu, Karine Fabienne Malagu, Nuria Merayo Merayo, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung, Gang Zhao
  • Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
    Publication number: 20180244611
    Abstract: The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: February 23, 2018
    Publication date: August 30, 2018
    Inventors: Robert J. Altenbach, Andrew Bogdan, Nicolas Desroy, Gregory A. Gfesser, Stephen N. Greszler, Philip R. Kym, Bo Liu, Karine Fabienne Malagu, Nuria Merayo Merayo, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung, Gang Zhao
  • Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors
    Patent number: 10035800
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y3, A1, A2, A3 and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: July 31, 2018
    Assignee: AbbVie Inc.
    Inventors: Steven D. Fidanze, Dauchun Liu, Robert A. Mantei, Keith F. McDaniel, John Pratt, George S. Sheppard, Le Wang, Andrew Bogdan, James H. Holms, Justin D. Dietrich, Jasmina Marjanovic, Lisa A. Hasvold, Yujia Dai
  • Substituted pyrrolidines and methods of use
    Patent number: 9981910
    Abstract: The invention discloses compounds of Formula (I) wherein R1, R2, R2A, R3, R3A, R4, R4A, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: May 29, 2018
    Assignees: AbbVie S.á.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Elsa De Lemos, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Stephen N. Greszler, Christopher Gaëtan Housseman, John R. Koenig, Philip R. Kym, Bo Liu, Marc J. Scanio, Xenia Searle, Xueqing Wang, Ming C. Yeung, Gang Zhao
  • 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use
    Patent number: 9969693
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav 1.7 and/or Nav 1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: May 15, 2018
    Assignee: AbbVie Inc.
    Inventors: Andrew Bogdan, Marlon D. Cowart, David A. DeGoey, Tammie K. Jinkerson, John R. Koenig, Michael E. Kort, Bo Liu, Mark A. Matulenko, Derek W. Nelson, Meena V. Patel, Hillary Peltier, Marc J. Scanio, Brian D. Wakefield
  • Substituted Pyrrolidines and Methods of Use
    Publication number: 20180099932
    Abstract: The invention discloses compounds of Formula (I) wherein R1, R2, R2A, R3, R3A, R4, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: October 3, 2017
    Publication date: April 12, 2018
    Inventors: Robert J. Altenbach, Andrew Bogdan, Nicolas Desroy, Gregory A. Gfesser, Stephen N. Greszler, John R. Koenig, Philip R. Kym, Bo Liu, Marc J. Scanio, Xenia Searle, Xueqing Wang, Ming C. Yeung, Gang Zhao
  • Substituted Pyrrolidines and Methods of Use
    Publication number: 20180099931
    Abstract: The invention discloses compounds of Formula (I) wherein R1, R2, R2A, R3, R3A, R4, R4A, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: October 5, 2017
    Publication date: April 12, 2018
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Elsa De Lemos, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Stephen N. Greszler, Christopher Gaëtan Housseman, John R. Koenig, Philip R. Kym, Bo Liu, Marc J. Scanio, Xenia Searle, Xueqing Wang, Ming C. Yeung, Gang Zhao